1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4.
Voice of Customer
5.
Global Schizophrenia
Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1.
By Value
5.2. Market Share & Forecast
5.2.1.
By Drug Class (First Generation Drugs, Second Generation
Drugs, Third Generation Drugs)
5.2.2.
By
Route Of Administration (Injectable, Oral)
5.2.3. By
Region (North America, Europe, Asia Pacific, South America, Middle East &
Africa)
5.2.4. By
Company (2022)
5.3. Market Map
5.3.1
By Drug Class
5.3.2 By Route of Administration
5.3.3 By Region
6.
North America
Schizophrenia Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1.
By Value
6.2. Market Share & Forecast
6.2.1. By Drug
Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
6.2.2.
By
Route Of Administration (Injectable, Oral)
6.2.3.
By Country
6.3. North America: Country Analysis
6.3.1.
United States
Schizophrenia Drugs Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Drug Class
6.3.1.2.2.
By Route of
Administration
6.3.2.
Canada Schizophrenia
Drugs Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Drug Class
6.3.2.2.2.
By Route of
Administration
6.3.3.
Mexico Schizophrenia
Drugs Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Drug Class
6.3.3.2.2.
By Route of
Administration
7.
Europe Schizophrenia
Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1.
By Value
7.2. Market Share & Forecast
7.2.1.
By Drug Class (First Generation Drugs, Second Generation
Drugs, Third Generation Drugs)
7.2.2.
By
Route Of Administration (Injectable, Oral)
7.2.3.
By Country
7.3. Europe: Country Analysis
7.3.1.
France Schizophrenia
Drugs Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Drug Class
7.3.1.2.2.
By Route of
Administration
7.3.2.
Germany
Schizophrenia Drugs Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Drug Class
7.3.2.2.2.
By Route of
Administration
7.3.3.
United Kingdom
Schizophrenia Drugs Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Drug Class
7.3.3.2.2.
By Route of Administration
7.3.4.
Italy Schizophrenia
Drugs Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Drug Class
7.3.4.2.2.
By Route of
Administration
7.3.5.
Spain Schizophrenia
Drugs Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Drug Class
7.3.5.2.2.
By Route of
Administration
8.
Asia-Pacific
Schizophrenia Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1.
By Value
8.2. Market Share & Forecast
8.2.1.
By Drug Class (First Generation Drugs, Second Generation
Drugs, Third Generation Drugs)
8.2.2.
By
Route Of Administration (Injectable, Oral)
8.2.3.
By Country
8.3. Asia-Pacific: Country Analysis
8.3.1.
China Schizophrenia
Drugs Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Drug Class
8.3.1.2.2.
By Route of
Administration
8.3.2.
India Schizophrenia
Drugs Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Drug Class
8.3.2.2.2.
By Route of
Administration
8.3.3.
Japan Schizophrenia
Drugs Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Drug Class
8.3.3.2.2.
By Route of Administration
8.3.4.
South Korea
Schizophrenia Drugs Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Drug Class
8.3.4.2.2.
By Route of
Administration
8.3.5.
Australia
Schizophrenia Drugs Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Drug Class
8.3.5.2.2.
By Route of
Administration
9.
South America
Schizophrenia Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1.
By Value
9.2. Market Share & Forecast
9.2.1.
By Drug Class (First
Generation Drugs, Second Generation Drugs, Third Generation Drugs)
9.2.2.
By Route Of
Administration (Injectable, Oral)
9.2.3.
By Country
9.3. South America: Country Analysis
9.3.1.
Brazil Schizophrenia
Drugs Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Drug Class
9.3.1.2.2.
By Route of
Administration
9.3.2.
Argentina Schizophrenia
Drugs Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Drug Class
9.3.2.2.2.
By Route of
Administration
9.3.3.
Colombia
Schizophrenia Drugs Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Drug Class
9.3.3.2.2.
By Route of
Administration
10.
Middle East and
Africa Schizophrenia Drugs Market Outlook
10.1.
Market Size &
Forecast
10.1.1.
By Value
10.2.
Market Share &
Forecast
10.2.1.
By Drug Class (First Generation Drugs, Second Generation
Drugs, Third Generation Drugs)
10.2.2.
By
Route Of Administration (Injectable, Oral)
10.2.3.
By Country
10.3.
MEA: Country
Analysis
10.3.1.
South Africa
Schizophrenia Drugs Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Drug Class
10.3.1.2.2.
By Route of
Administration
10.3.2.
Saudi Arabia
Schizophrenia Drugs Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Drug Class
10.3.2.2.2.
By Route of
Administration
10.3.3.
UAE Schizophrenia
Drugs Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Drug Class
10.3.3.2.2.
By Route of Administration
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Recent Development
12.2.
Mergers &
Acquisitions
12.3.
Product Launches
13.
Global Schizophrenia Drugs Market: SWOT Analysis
14.
Porter’s Five Forces Analysis
14.1.
Competition in the
Industry
14.2.
Potential of New
Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute
Products
15. Competitive Landscape
15.1.
Alkermes Plc
15.1.1.
Business Overview
15.1.2.
Product Offerings
15.1.3.
Recent Developments
15.1.4.
Financials (As
Reported)
15.1.5.
Key Personnel
15.1.6.
SWOT Analysis
15.2.
Eli Lilly and Company.
15.3.
Johnson &
Johnson.
15.4.
AstraZeneca.
15.5.
Pfizer Inc.
15.6.
AbbVie Inc.
15.7.
Otsuka
Pharmaceutical Inc.
15.8.
Bristol-Myers Squibb
Company.
15.9.
Sumitomo Dainippon
Pharma.
15.10.
Acadia
Pharmaceuticals.
16. Strategic Recommendations